NRSN (NeuroSense Therapeutics) Common Stock: $0.00 Mil (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Common Stock?

NeuroSense Therapeutics NRSN -0.21% 29 Common Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Common Stock Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
NeuroSense Therapeutics (NRSN) has a Common Stock of $0.00 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Common Stock too high?
NeuroSense Therapeutics' current Common Stock is $0.00 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Common Stock compare to SNTI and LSTA?
NeuroSense Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Common Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price